A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with confirmed diagnosis of r/r iNHL
Patients ages ≥ 18 years old when first dosed with copanlisib for iNHL.
Patients who will receive copanlisib or received at least one dose of copanlisib after 01-Nov-2019
Patients or his/her legal guardian or representative agree to provide the written informed consent or a waiver of informed consent granted by local IRB
You may not be if
Patients who had participated in the global clinical study for copanlisib before local market approval
Patients who participate in an interventional trial during the data collection period
Clareo Health | A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
